Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring ...

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025Phase 1b/2 Multiple Ascending Dose ...

The third quarter marked an important inflection point for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics (KLRS).

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Home OCT and AI significantly improve early detection and treatment adjustments in neovascular AMD, enhancing patient ...

Lotery cautioned that AI's use in eye care has limitations. "AI models may underperform on underrepresented populations, AI trained on specific datasets may not transfer well across clinical settings, ...

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age ...

PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and ...

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate ...

Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degeneration Neovascular or “wet” ...